Cloning murine antibody V-genes with non-degenerate primers and conversion to a recombinant antibody format.

Cloning murine antibody V-genes with non-degenerate primers and conversion to a recombinant antibody format. Monoclon Antib Immunodiagn Immunother. 2014 Dec;33(6):369-77 Authors: Bialon M, Schellenberg L, Herzog N, Kraus S, Jörißen H, Fischer R, Stein C, Nähring J, Barth S, Püttmann C Abstract Monoclonal antibodies are produced in cultured hybridoma cell lines, but these cells tend to be unstable; it is therefore necessary to rescue the corresponding genetic information. Here we describe an improved method for the amplification of antibody variable gene (V-gene) information from murine hybridoma cells using a panel of specific, non-degenerate primers. This primer set allows sequences to be rescued from all murine V-genes, except the lambda light chain genes, which rarely contribute to murine immune diversity. We tested the primers against a range of antibodies and recovered specific amplification products in all cases. The heavy and light chain variable regions were subsequently joined by a two-step cloning strategy or by splice overlap extension PCR. PMID: 25545205 [PubMed - in process]
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research

Related Links:

This article gives an overview of the current results of PET with radiolabelled amino acids in therapy monitoring of standard therapy as well as various innovative approaches in the treatment of patients with cerebral gliomas.Expert opinion: Amino acid PET has proven to be helpful in therapy monitoring of gliomas, the costs are low in relation to the costs of therapy and the clinical benefit, and a widespread clinical use is highly desirable. PMID: 31829748 [PubMed - as supplied by publisher]
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
Publication date: Available online 12 December 2019Source: Pharmacological ResearchAuthor(s): Qianqian Liu, Jiao Qu, Mingxia Zhao, Qiang Xu, Yang SunAbstractSrc homology 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2) is a major phosphatase involved in several cellular processes. In recent years, SHP2 has been the focus of significant attention in human diseases, particular in cancer. Several studies have shown that SHP2 plays an important role in regulating immune cell functions in tumor microenvironment. A few clinical trials conducted using SHP2 allosteric inhibitors have shown remarkable anti-tumor benefits an...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 12 December 2019Source: Autoimmunity ReviewsAuthor(s): Ruth Percik, Gadi Shlomai, Amir Tirosh, Amit Tirosh, Raya Leibowitz-Amit, Yael Eshet, Gahl Greenberg, Alex Merlinsky, Ehud Barhod, Yael Steinberg-Silman, Tal SellaAbstractObjectiveImmune checkpoint inhibitors have introduced a new and heterogeneous class of immune-related adverse effects, with the endocrine system being a predominant target for autoimmunity. Autoimmune hypothalamic-pituitary-adrenal axis (HPA) diseases induced by checkpoint inhibitors are being increasingly recognized. We aimed to characterize the spectrum of checkpoi...
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research
Authors: Reck M, Shankar G, Lee A, Coleman S, McCleland M, Papadimitrakopoulou VA, Socinski MA, Sandler A Abstract Introduction: Cancer immunotherapy has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). However, specific patient groups (e.g. patients with activating epidermal growth factor receptor [EGFR] mutations) do not appear to derive benefit from immune checkpoint inhibitor (ICI) monotherapy. Combining ICIs, such as atezolizumab, with chemotherapy and/or targeted therapies may help to address this unmet need.Areas covered: Atezolizumab is an anti-program...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
CONCLUSION: Following OIT, the assessment using exercise provocation tests should be performed prior to termination of exercise restriction because some patients remain intolerant to exercise. PMID: 31827029 [PubMed - in process]
Source: Allergology International - Category: Allergy & Immunology Tags: Arerugi Source Type: research
Publication date: Available online 13 December 2019Source: Journal of BiotechnologyAuthor(s): Jaime I. Arevalo-Villalobos, Dania O. Govea Alonso, Sergio Rosales-MendozaAbstractSynucleinopathies are conditions that remain with no available effective treatments thus far. Immunotherapy is a possible path to fight against such pathologies by inducing antibodies against alpha-synuclein (α-Syn), which could induce the clearance of its pathologic form. Looking to develop a new low-cost, effective vaccine against synucleinopathies; we have designed a chimeric plant-made antigen comprising the subunit B of the enterotoxin fro...
Source: Journal of Biotechnology - Category: Biotechnology Source Type: research
Two separate studies reach very different endpoints with addition of immunotherapy in triple-negative breast cancer. Researchers are now asking why.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
A late-stage clinical trial has shown therapy combining Roche's immunotherapy Tecentriq with two of its other drugs helped people with a form of advanced melanoma, the Swiss drugmaker said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
             Basel, 13 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). The study showed adding Tecentriq ® (atezolizumab) to Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and Zelboraf. A significant and clinically meaningful improvement in PFS was demonstrated in the study. The safety ...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Contributor : Sidi ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusEvading immune destruction is a hallmark of cancer and a key feature for the resistance to cancer immunotherapy. Genetic alterations can directly influence the nature of cancer cells in the native tumor microenvironment to mediate immune escape. Our genome-scale in vivo CRISPR screens robustly identified multiple regulators of tumor-intrinsic factors that alter the ability of cells to grow as tumors across different levels of immunocompetence. As a convergent hit from these screens, Prkar1a mutant cells are able to...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
More News: Genetics | Immunotherapy | Microbiology